Abstract
A new trial provides further evidence that rituximab treatment can reduce the risk of relapse in children with steroid-dependent idiopathic nephrotic syndrome. Addition of a single infusion of rituximab to steroid therapy was associated with a decrease in proteinuria at 3 months and a significant increase in the relapse-free period.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Comment
MeSH terms
-
Anti-Inflammatory Agents / adverse effects*
-
Female
-
Humans
-
Immunologic Factors / therapeutic use*
-
Male
-
Nephrotic Syndrome / drug therapy*
-
Prednisone / adverse effects*
-
Rituximab / therapeutic use*
Substances
-
Anti-Inflammatory Agents
-
Immunologic Factors
-
Rituximab
-
Prednisone